Please assess the completion status of the following clinical trial:

Trial Title: Oxybutynin and Omega-3 for OAB (Overactive Bladder)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women between the ages of 18-85; Desiring treatment for symptoms of urinary frequency, defined as \>8 voids/day and/or nocturia \> 1 void/night or urge incontinence episodes of \>1/day~Exclusion Criteria:~Bleeding disorder; Uncontrolled diabetes; Hypotension; Liver disease, such as hepatitis A/B/C, cirrhosis, acute fatty liver, liver tumors; Post voiding residual (PVR) \> 150 on more than one occasion; Uncontrolled narrow-angle glaucoma; Hematuria of unknown cause; Obstructive uropathy; Known hypersensitivity to study medications; Recent use of study/omega 3 or anticholinergic medication in the prior 3 weeks with an inability to discontinue this medication; Planning any surgery in the 6 weeks of study duration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Omega- 3 Fatty Acid (Type: EXPERIMENTAL): The patient will receive oxybutynin 5 mg twice daily (BID). The patients in the study group will receive a 0.9 gm capsule of Omega-3 BID. The amount of medication was chosen based on dosage used in prior studies and the current FDA recommendations to not exceed 2gm/day of omega-3 in dietary supplementation.
- Placebo (Type: PLACEBO_COMPARATOR): Seagate® Extra Virgin Olive oil capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).